HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical trial (AK112-310/HARMONi-GI2) of ivonescimab, a first-in-class PD-1/VEGF bispecific...
Hence then, the article about akeso announces first patient enrollment in phase iii trial of ivonescimab for pancreatic cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer )
Also on site :
- Ronaldo’s last World Cup? We will see, says Portugal star before Spain clash
- The supertanker tycoon making millions on Hormuz ‘shuttle runs’
- Another French museum robbed despite ‘special attention’ after Louvre heist